First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Fredrik Schjesvold, Tomas Jelinek, Kamila Polgarova, Ludek Pour, Sung-Soo Yoon, Won Seog Kim, Alexander Fosså, Jesús F. San-Miguel, Miguel Canales, Paula Rodríguez-Otero, Albert Oriol, Javier de la Rubia, Joaquín Martínez-Lopez, Sonia González De Villambrosia, Prashant Kapoor, Ola Landgren, James Edward Hoffman, Noopur Raje, Hongfang Wang, Kunal Jhunjhunwala, Liang Zhao, Zhini Wang, Mony Morisse, Helgi Van de Velde, Nitya Nathwani
Institutions: Oslo University Hospital, University of Ostrava, University Hospital Ostrava, Charles University, Masaryk University, University Hospital Brno, Seoul National University, Seoul National University Hospital, Samsung Medical Center, Sungkyunkwan University, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, Institut Català d'Oncologia, Hospital Universitari i Politècnic La Fe, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Mayo Clinic, Sylvester Comprehensive Cancer Center, University of Miami, Massachusetts General Hospital, Sanofi (China), City Of Hope National Medical Center, City of Hope
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405041996